Document is current
Any future updates will be listed below
-
Authors
Lawton, Julia https://orcid.org/0000-0002-8016-7374
Adler, Amanda I. https://orcid.org/0000-0002-2797-3385
Brennan, Amanda https://orcid.org/0000-0002-9541-2221
Holt, Richard I. G. https://orcid.org/0000-0001-8911-6744
Hovorka, Roman https://orcid.org/0000-0003-2901-461X
Kadiyala, Nithya https://orcid.org/0000-0003-4285-4656
Lau, Dawn
Peacock, Marian https://orcid.org/0000-0001-7499-0439
Boughton, Charlotte K. https://orcid.org/0000-0003-3272-9544
Rankin, David https://orcid.org/0000-0002-5835-3402
-
Funding
Funding for this research was provided by:
Efficacy and Mechanism Evaluation Programme (NIHR 132299)
- License Information
-
More Information
Article History
Received: 6 October 2025
Accepted: 11 June 2026
First Online: 7 July 2026
Declarations
:
: This study was approved by the East of England- Cambridge South Research Ethics Committee (UK) (#22/EE/0164) and was conducted in accordance with the declaration of Helsinki. All participants were provided with verbal and written information about the trial and procedures involved in the (interview) study and gave their written informed consent prior to participation.
: All participants gave their consent for data to be used in publications arising from this study.
: RH reports having received speaker honoraria from Eli Lilly, Dexcom and Novo Nordisk, receiving license fees from Braun; receiving consultancy fees from Abbott Diabetes Care, patents related to closed-loop, and being director at CamDiab. CKB has received consultancy fees from CamDiab, speaker honoraria from Ypsomed and research support from Abbott Diabetes Care, Dexcom and Ypsomed. All other authors declare that they have no competing interests.
